Indeed, the temporally distinct expression of PD-1 by different T cell subsets, similar to a recently described PD-1+ Teff/TReg balance in the tumor microenvironment72, may explain why early studies using antibody-mediated blockade of PD-1 during late stages of EAE observed no effect on disease development52. The gene discussed is PDCD1; the disease is neoplasm.